- #1
pinball1970
Gold Member
- 3,231
- 4,707
- TL;DR Summary
- https://www.bmj.com/content/375/bmj.n2635
In her 25 September email to the FDA Jackson wrote that Ventavia had enrolled more than 1000 participants at three sites. The full trial (registered under NCT04368728) enrolled around 44 000 participants across 153 sites that included numerous commercial companies and academic centres. Many concerns raised.
Not what we want want to be reading in the BMJ at this time regarding trial integrity.
The Vaccine works, the data is overwhelming but this casts a shadow on the integrity of the trials and the Science community as a whole (especially seen from the tax payer/layman perspective)
Science guys seen this? Thoughts? Or is the human factor that is part and parcel of the process?
Thanks in advance.
The Vaccine works, the data is overwhelming but this casts a shadow on the integrity of the trials and the Science community as a whole (especially seen from the tax payer/layman perspective)
Concerns raised
In her 25 September email to the FDA Jackson wrote that Ventavia had enrolled more than 1000 participants at three sites. The full trial (registered under NCT04368728) enrolled around 44 000 participants across 153 sites that included numerous commercial companies and academic centres. She then listed a dozen concerns she had witnessed, including:- Participants placed in a hallway after injection and not being monitored by clinical staff
- Lack of timely follow-up of patients who experienced adverse events
- Protocol deviations not being reported
- Vaccines not being stored at proper temperatures
- Mislabelled laboratory specimens, and
- Targeting of Ventavia staff for reporting these types of problems.
Science guys seen this? Thoughts? Or is the human factor that is part and parcel of the process?
Thanks in advance.